<DOC>
	<DOCNO>NCT02205138</DOCNO>
	<brief_summary>Among exist surgical technique , spinal fusion consider gold standard treat broad spectrum degenerative spine disorder , include spondylolisthesis scoliosis , regard pain reduction functional improvement . However , pseudarthrosis failure relieve low back pain unfortunately still frequent , irrespective type procedure graft use surgeon . The present Phase 2a study aim demonstrate safety efficacy ALLOBÂ® , proprietary population allogeneic osteoblastic cell , lumbar spinal fusion .</brief_summary>
	<brief_title>Phase 2a Study Allogeneic Osteoblastic Cells Implantation Lumbar Spinal Fusion</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Ability provide write , date , sign informed consent prior study related procedure , understand comply study requirement Symptomatic degenerative disc disease lumbar spine require single level lumbar fusion ( L1S1 ) Unresponsive nonoperative treatment least 6 month Lumbar disc disease require treatment one level Previous fail fusion involve lumbar level Local active latent infection involve lumbar level Positive serology hepatitis B , hepatitis C , HIV Current past medical disease could interfere evaluation safety efficacy , judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Spinal Fusion</keyword>
	<keyword>Lumbar Interbody Fusion</keyword>
	<keyword>Degenerative Disc Disease</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Bone Graft</keyword>
</DOC>